Illumina told EU judges today that the European Commission had no right to seize jurisdiction over its acquisition of cancer-testing company Grail, and ran roughshod over its procedural rights.
The US gene-sequencing company was at the EU General Court to challenge the commission’s acceptance of a referral request from France, which